Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting

•Although all patients were able to access HCV DAA therapy, 35% of patients required an insurance appeal process.•Median time from transplant to first dose was 45 days.•Prior authorization denials necessitating insurance appeals led to delays in therapy.•Patient cost was minimal after utilization of copay assistance programs, which are a limited resource.•Access to DAA therapy for solid-organ transplant patients may require added administrative efforts to complete the insurance approval process.